AMNEAL PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-12-31 was 73.37K shares.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-09-30 was 114.44K shares.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 712.07K shares, a 79.40% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 396.91K shares, a 142.28% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 163.82K shares, a 21.03% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 207.45K shares, a 39.40% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 712.07K shares 10-K · filed 2026-02-27 | |
| 2024-12-31 | 396.91K shares 10-K · filed 2026-02-27 | |
| 2023-12-31 | 163.82K shares 10-K · filed 2026-02-27 | |
| 2022-12-31 | 207.45K shares 10-K · filed 2025-02-28 | |
| 2021-12-31 | 342.35K shares 10-K · filed 2024-03-14 | |
| 2020-12-31 | 116.68K shares 10-K · filed 2023-03-03 | |
| 2019-12-31 | 210.81K shares 10-K · filed 2022-03-01 | |
| 2018-12-31 | 73.37K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | 351.67K shares 10-K · filed 2021-03-01 |
| 2018-09-30 | 114.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |